Cytek Biosciences is forecast to grow earnings and revenue by 114.8% and 12.2% per annum respectively. EPS is expected to grow by 114.8% per annum. Return on equity is forecast to be 10% in 3 years.
Key information
114.8%
Earnings growth rate
114.8%
EPS growth rate
Life Sciences earnings growth
26.4%
Revenue growth rate
12.2%
Future return on equity
10.0%
Analyst coverage
Good
Last updated
11 Nov 2024
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
DB:8EQ - Analysts future estimates and past financials data (USD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2026
262
10
N/A
N/A
4
12/31/2025
234
5
N/A
N/A
6
12/31/2024
205
-9
N/A
N/A
6
9/30/2024
201
-10
29
33
N/A
6/30/2024
198
-18
11
15
N/A
3/31/2024
201
-12
1
6
N/A
12/31/2023
193
-12
0
5
N/A
9/30/2023
183
-14
-8
2
N/A
6/30/2023
176
-6
-11
-1
N/A
3/31/2023
166
-2
-17
-8
N/A
12/31/2022
164
2
-22
-12
N/A
9/30/2022
155
-1
-18
-13
N/A
6/30/2022
148
-3
-9
-4
N/A
3/31/2022
139
-2
-3
1
N/A
12/31/2021
128
0
0
5
N/A
9/30/2021
120
1
8
11
N/A
6/30/2021
110
2
9
12
N/A
3/31/2021
99
4
14
16
N/A
12/31/2020
93
3
14
15
N/A
12/31/2019
58
-17
-15
-14
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 8EQ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: 8EQ is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 8EQ is expected to become profitable in the next 3 years.
Revenue vs Market: 8EQ's revenue (12.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 8EQ's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 8EQ's Return on Equity is forecast to be low in 3 years time (10%).